Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlobalData Plc
  6. News
  7. Summary
    DATA   GB00B87ZTG26


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

GlobalData : Low level of innovation and generic competition to result in the neuroendocrine tumor market growing only 0.9% by 2030, says GlobalData

09/28/2021 | 02:02pm EDT
28 Sep 2021
Low level of innovation and generic competition to result in the neuroendocrine tumor market growing only 0.9% by 2030, says GlobalData
Posted in Pharma

The market for neuroendocrine tumors (NETs) - a rare type of tumor where cancerous growth can begin in any cell within the hormone or nervous system - is expected to see a very slow 0.9% compound annual growth rate (CAGR) over the next decade in the world's eight major markets (8MM*) due to substantial generic erosion and low levels of innovation, according to GlobalData. The leading data and analytics company notes that this may turn around after 2030 with the development of molecules currently in the early-stage pipeline.

According to GlobalData's latest report, 'Neuroendocrine Tumors - Global Drug Forecast and Market Analysis to 2030', the NET market will grow from $3.11bn in 2020 to $3.41bn in 2030 across the 8MM.

Sakis Paliouras, PhD, Senior Oncology Analyst at GlobalData, comments: "The most ground-breaking development in the treatment of patients with NETs has been the emergence of peptide receptor radionuclide therapy (PRRT), with the FDA's approval of Novartis' Lutathera in 2018. Lutathera has tackled a distinct unmet need for patients progressing on somatostatin analogs and has been very commercially successful so far. GlobalData forecasts the drug to grow further, reaching $699m in peak sales."

GlobalData expects five pipeline agents to receive marketing authorization in the next decade. Of these, Isotopen Technologien Munchen's (ITM) PRRT molecule Solucin and Junshi Bio's immune checkpoint inhibitor Tuoyi are forecast to see the highest clinical use. Furthermore, the newly approved kinase inhibitor Hutchmed's Sulanda is expected to achieve significant commercial success, with $231m in peak sales.

Paliouras continues: "Four currently marketed agents, Novartis' Sandostatin LAR and Afinitor, Ipsen's Somatuline Depot, and Pfizer's Sutent, are responsible for over 80% of this market's value. All these agents will go off-patent during the forecast period and experience substantial generic erosion, especially easy-to-manufacture compounds Afinitor and Sutent. This is expected to lead to a great decline in market growth that will only be modestly counterbalanced by approvals of pipeline agents and expansions in new markets."

"Key opinion leaders (KOLs) interviewed by GlobalData believe that among the most important unmet needs are new predictive biomarkers that can match a patient to the most appropriate therapy, as well as the need for additional insight into when it is feasible to stop treatment or re-treat patients with PRRT. The lack of innovation by current late-stage pipeline agents raises the possibility of a true paradigm shift happening after 2030, coming about by molecules that are now in the early-stage pipeline such as alpha-emitting PRRT drugs and antibody-drug conjugates."

*8MM = US, France, Germany, Italy, Spain, the UK, Japan, and China


GlobalData plc published this content on 28 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2021 18:01:06 UTC.

ę Publicnow 2021
All news about GLOBALDATA PLC
07:38aUK joins global AI arms race with new ten-year plan as it targets slice of global AI pl..
06:58aHeineken's Q3 sales impacted by renewed wellbeing trends following COVID-19 pandemic, s..
10/26Thailand pay-TV services market revenue to reach US$1.1bn in 2026, forecasts GlobalData
10/26Hong Kong payments market to grow by 6.1 percent in 2022
10/26Amazon to open New Zealand's first data center with global market set to reach $948bn b..
10/26Simpson Thacher & Bartlett and Kirkland & Ellis were top M&A legal advisers by value an..
10/26UK Government must do more to address rising COVID-19 Cases if UK is to have ‘nor..
10/26Tesco's late entry into checkout-free race won't stop it reaping rewards as ‘ambi..
10/26India to account for over 50% of upcoming crude oil refinery projects in Asia by 2025, ..
10/26Mk-54 torpedoes procurement to bolster Indian Navy anti-submarine warfare capabilities,..
More news
Sales 2021 192 M 263 M 263 M
Net income 2021 27,9 M 38,2 M 38,2 M
Net Debt 2021 50,8 M 69,7 M 69,7 M
P/E ratio 2021 61,4x
Yield 2021 1,32%
Capitalization 1 622 M 2 236 M 2 227 M
EV / Sales 2021 8,73x
EV / Sales 2022 8,03x
Nbr of Employees 3 472
Free-Float 30,8%
Duration : Period :
GlobalData Plc Technical Analysis Chart | DATA | GB00B87ZTG26 | MarketScreener
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 1 375,00 GBX
Average target price 1 592,50 GBX
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Michael Thomas Danson Chief Executive Officer & Director
Sally Kate Miranda Johnson Chief Financial Officer
Murray Legg Independent Non-Executive Chairman
Peter Martin Harkness Independent Non-Executive Director
Catherine Birkett Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
S&P GLOBAL INC.41.34%111 918
RELX PLC25.13%59 618
MSCI INC.44.03%53 020
EQUIFAX INC.42.49%33 059